Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Jubelirer

Surgery Abington, PA Medical Doctor

NPI 1376522011 CMS profile 16202

1245 Highland Ave, Suite 600, Abington, PA 19001

Open in the dashboard

General payments

$2,781

106 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Jubelirer of Abington, PA is reported in the CMS Open Payments database as having received $2,781 across 106 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $254 12
2024 General $1,000 30
2023 General $542 27
2022 General $286 8
2021 General $123 4
2020 General $148 7
2019 General $430 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Jubelirer
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Robert Jubelirer were reported at $254. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Robert Jubelirer Surgery median Middle half National median
2019 $430 $253 $82–$1,521 $163
2020 $148 $131 $40–$706 $114
2021 $123 $168 $50–$904 $132
2022 $286 $224 $76–$1,218 $149
2023 $542 $253 $82–$1,255 $160
2024 $1,000 $279 $90–$1,381 $164
2025 $254 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $1,054 43 payments
  2. Medtronic, Inc. $158 2 payments
  3. Baxter Healthcare $120 3 payments
  4. W. L. Gore & Associates, Inc. $101 2 payments
  5. Next Science LLC $98 3 payments
  6. LeMaitre Vascular, Inc. $95 7 payments
  7. Boston Scientific Corporation $93 3 payments
  8. Cook Medical LLC $78 1 payment
  9. Organogenesis Inc. $75 4 payments
  10. Urgo Medical North America, LLC $75 3 payments
  11. Other $834 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,781 106 payments
Products named General payments · program years 2019–2025
  1. GRAFIX PL $310 8 payments
  2. OASIS Extra Cellular Matrix $296 6 payments
  3. STRAVIX PL $284 6 payments
  4. STRAVIX $232 4 payments
  5. ENDURANT IIS $142 1 payment
  6. OASIS Extra Cellular Matrix $116 1 payment
  7. GRAFIX $116 1 payment
  8. COLLAGENASE SANTYL $112 9 payments
  9. PERCLOT $95 2 payments
  10. ARTEGRAFT VASCULAR GRAFT $95 7 payments
  11. Other $2,244 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

398

Median for General Surgery: 59

Drug cost

$73,117

Median for General Surgery: $393

Branded share of claims

48.5%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 50 $34,786
Xarelto Rivaroxaban Brand 28 $24,595
Eliquis Apixaban Brand 16 $9,181
Cilostazol Generic 55 $1,478
Pentoxifylline Generic 31 $901
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 39 $653
Atorvastatin Calcium Generic 20 $439
Ammonium Lactate Generic 22 $420
Clopidogrel Clopidogrel Bisulfate Brand 12 $193
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 48 $133

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$131,360

Medicare's payments for the services billed

Medicare patients

415

Average age 76

Services billed

1,255

204 women, 211 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Chronic kidney disease 53%
Diabetes 45%
Ischemic heart disease 44%
Heart failure 38%
Atrial fibrillation 33%
Depression 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

106 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record